Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.

  title={Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.},
  author={Susan A. Charman and Sarah J Arbe-Barnes and Ian C. Bathurst and Reto Brun and Michael L. Campbell and William Neil Charman and Francis C. K. Chiu and Jacques Chollet and Judith Craft and Darren John Creek and Yuxiang Dong and Hugues Matile and Melanie Maurer and Julia Morizzi and Tien An Nguyen and Petros Papastogiannidis and Christian Scheurer and David M Shackleford and Kamaraj Sriraghavan and Lukas Stingelin and Yuanqing Tang and Heinrich Urwyler and Xiaofang Wang and Karen L. White and Sergio Wittlin and Lin Zhou and Jonathan L. Vennerstrom},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  volume={108 11},
Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase IIa trials in malaria patients. Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clinical drug development candidate. In vitro, OZ439 is fast… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 94 extracted citations

Antimalaria Drug Development & Pipeline

View 3 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 37 references

The role of Product Development Partnerships in research and development for neglected diseases

K Griesbaum, XJ Liu, A Kassiaris, M Scherer
In Health • 2010

Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277

L Zhou
Bioorg Med Chem Lett 18:1555–1558 • 2008

Similar Papers

Loading similar papers…